ziltivekimab

Novo Nordisk Shares Fall After Heart Drug Trial Fails

Novo Nordisk's shares dropped significantly after its late-stage heart drug ziltivekimab failed to reduce major adverse cardiovascular events in a trial. This marks another setback for the Danish drugmaker, impacting investor confidence in its pipeline.